Comprehensive Evaluation of the NeoBase 2 Non-derivatized MSMS Assay and Exploration of Analytes With Significantly Different Concentrations Between Term and Preterm Neonates
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Despite the popularity of the NeoBase 2 Non-derivatized MSMS assay (PerkinElmer, Turku, Finland), there are no reports of its comprehensive evaluation, including the ability to distinguish transient tyrosinemia of the newborn (TTN) from tyrosinemia type 1 (TYR 1) using succinylacetone (SUAC). No newborn screening (NBS) cutoffs for preterm neonates in the Korean population have been suggested. We evaluated the NeoBase 2 assay and identified analytes requiring different cutoffs in preterm neonates. Methods: Residual NBS dried blood spot samples and proficiency testing (PT) materials of the Newborn Screening Quality Assurance Program and the Korean Association of External Quality Assessment Service were used. Precision, accuracy, limit of detection (LOD), lower limit of quantification (LLOQ), linearity, recovery, carryover, and performance of SUAC were evaluated. Cutoffs were determined, and analytes requiring different cutoffs in preterm neonates were investigated. Results: Mean CVs for within-run and between-day precision were within 15%. Accuracy analysis indicated high agreement with in-house derivatized assay results and results of other PT participants. All analytes demonstrated acceptable LOD, LLOQ, and linearity. Recoveries were acceptable, except for SUAC. Carryover was negligible. Cutoffs were established for all analytes; Tyr, adenosine, and C20:0-lysophosphatidylcholine required different cutoffs in preterm neonates. Differential diagnosis of TYR 1 and TTN was successful with simultaneous Tyr and SUAC measurement. Conclusions: The NeoBase 2 assay demonstrated satisfactory performance. The additional analytes provide a wider diagnostic coverage, and the simultaneous measurement of Tyr and SUAC is efficient in excluding TYR 1. The new cutoffs for preterm neonates may decrease false-positive rates, without compromising diagnostic sensitivity.
Abstract
Background: Despite the popularity of the NeoBase 2 Non-derivatized MSMS assay (PerkinElmer, Turku, Finland), there are no reports of its comprehensive evaluation, including the ability to distinguish transient tyrosinemia of the newborn (TTN) from tyrosinemia type 1 (TYR 1) using succinylacetone (SUAC). No newborn screening (NBS) cutoffs for preterm neonates in the Korean population have been suggested. We evaluated the NeoBase 2 assay and identified analytes requiring different cutoffs in preterm neonates. Methods: Residual NBS dried blood spot samples and proficiency testing (PT) materials of the Newborn Screening Quality Assurance Program and the Korean Association of External Quality Assessment Service were used. Precision, accuracy, limit of detection (LOD), lower limit of quantification (LLOQ), linearity, recovery, carryover, and performance of SUAC were evaluated. Cutoffs were determined, and analytes requiring different cutoffs in preterm neonates were investigated. Results: Mean CVs for within-run and between-day precision were within 15%. Accuracy analysis indicated high agreement with in-house derivatized assay results and results of other PT participants. All analytes demonstrated acceptable LOD, LLOQ, and linearity. Recoveries were acceptable, except for SUAC. Carryover was negligible. Cutoffs were established for all analytes; Tyr, adenosine, and C20:0-lysophosphatidylcholine required different cutoffs in preterm neonates. Differential diagnosis of TYR 1 and TTN was successful with simultaneous Tyr and SUAC measurement. Conclusions: The NeoBase 2 assay demonstrated satisfactory performance. The additional analytes provide a wider diagnostic coverage, and the simultaneous measurement of Tyr and SUAC is efficient in excluding TYR 1. The new cutoffs for preterm neonates may decrease false-positive rates, without compromising diagnostic sensitivity.
참고문헌 (40)
- Schulze A, "Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications", Pediatrics, 111, pp.1399~1406 (2003)
- Wilcken B, "Screening newborns for inborn errors of metabolism by tandem mass spectrometry", N Engl J Med, 348, pp.2304~2312 (2003)
- "Newborn Screening Quality Assurance Program (NSQAP) 2020 Quality control program report" (2020)[URL]
- Cicalini I, "Analytical evaluation of the ideal strategy for high-throughput flow injection analysis by tandem mass spectrometry in routine newborn screening", Metabolites, 11, pp.473~ (2021)
- Zheng Y, "A verification of the application of the non-derivatized mass spectrometry method in newborns screening of metabolic disorders", Medicine(Baltimore), 98, pp.e15500~ (2019)
- "510(k) Premarket notification (K173568)" (2018)[URL]
- Levy HL, "Transient tyrosinemia in full-term infants", JAMA, 209, pp.249~250 (1969)
- Zea-Rey AV, "The incidence of transient neonatal tyrosinemia within a Mexican population", J Inborn Errors Metab Screen, 5, pp.e170016~ (2017)
- Park HD, "Clinical, biochemical, and genetic analysis of a Korean neonate with hereditary tyrosinemia type 1", Clin Chem Lab Med, 47, pp.930~933 (2009)
- Choi HJ, "Two novel FAH gene mutations in a patient with hereditary tyrosinemia type I", Ann Clin Lab Sci, 44, pp.317~323 (2014)
- Clark RH, "Gestational age and age at sampling influence metabolic profiles in premature infants", Pediatrics, 134, pp.e37~46 (2014)
- Gucciardi A, "Analysis and interpretation of acylcarnitine profiles in dried blood spot and plasma of preterm and full-term newborns", Pediatr Res, 77, pp.36~47 (2015)
- Liu Q, "Analysis of amino acids and acyl carnitine profiles in low birth weight, preterm, and small for gestational age neonates", J Matern Fetal Neonatal Med, 30, pp.2697~2704 (2017)
- Lee HS, "Arginine, as a key indicator for real-time stability monitoring of quality control in the newborn screening test using dried blood spot", Separations, 8, pp.201~ (2021)
- CLSI, "Newborn screening by tandem mass spectrometry. CLSI NBS04", Clinical and Laboratory Standards Institute, ~ (2017)
- CLSI, "Liquid chromatography-mass spectrometry methods; approved guideline. CLSI C62-A", Clinical and Laboratory Standards Institute, ~ (2014)
- 문수영, "임상검사실에서의 액체크로마토그래피-질량분석을 위한 권고안: 제2편. 검사법 검증", Laboratory Medicine Online, 10(2), pp.95~108 (2020), 대한진단검사의학회[DOI]
- Wickham H, "ggplot2: elegant graphics for data analysis", Use R, ~ (2016)
- CLSI, "Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline—third edition. CLSI EP28-A3C", Clinical and Laboratory Standards Institute, ~ (2010)
- "Newborn Screening Quality Assurance Program (NSQAP) 2020 Annual Summary Report" (2020)[URL]
- Soo-Youn Lee, "Report of the Korean Association of External Quality Assessment Service on Metabolite Testing (2018–2019)", Laboratory Medicine and Quality Assurance, 42(1), pp.10~25 (2020), 대한진단검사정도관리협회[DOI]
- 조성은, "한국에서 탠덤 질량분석기를 이용한 선천성 대사이상질환 신생아 선별검사: 일 개 전문 수탁기관의 경험", Laboratory Medicine Online, 5(4), pp.196~203 (2015), 대한진단검사의학회
- 채효진, "Use of Liquid Chromatography-Tandem Mass Spectrometry for Clinical Testing in Korean Laboratories: a Questionnaire Survey", Annals of Laboratory Medicine, 39(5), pp.447~453 (2019), 대한진단검사의학회[DOI]
- Choi Rihwa, "Quantification of Thioguanine in DNA Using Liquid Chromatography-Tandem Mass Spectrometry for Routine Thiopurine Drug Monitoring in Patients With Pediatric Acute Lymphoblastic Leukemia", Annals of Laboratory Medicine, 41(2), pp.145~154 (2021), 대한진단검사의학회[DOI]
- 최리화, "Dried Blood Spot Multiplexed Steroid Profiling Using Liquid Chromatography Tandem Mass Spectrometry in Korean Neonates", Annals of Laboratory Medicine, 39(3), pp.263~270 (2019), 대한진단검사의학회[DOI]
- Hall PL, "Postanalytical tools improve performance of newborn screening by tandem mass spectrometry", Genet Med, 16, pp.889~895 (2014)
- Saudubray J-M, "Inborn metabolic diseases: diagnosis and treatment", pp.656~ (2012), Springer
- Levy HL, "Routine newborn screening for histidinemia. Clinical and biochemical results", N Engl J Med, 291, pp.1214~1219 (1974)
- Lam WK, "Histidinaemia : a benign metabolic disorder", Arch Dis Child, 74, pp.343~346 (1996)
- Rappold Brian A., "Review of the Use of Liquid Chromatography-Tandem Mass Spectrometry in Clinical Laboratories: Part I-Development", Annals of Laboratory Medicine, 42(2), pp.121~140 (2022), 대한진단검사의학회[DOI]
- Pickens CA, "Harmonizing newborn screening laboratory proficiency test results using the CDC NSQAP reference materials", Int J Neonatal Screen, 6, pp.75~ (2020)
- CLSI, "Newborn screening for preterm, low birth weight, and sick newborns; approved guideline. 2nd ed. CLSI NBS03-A", Clinical and Laboratory Standards Institute, ~ (2019)
- Panfoli I, "Why do premature newborn infants display elevated blood adenosine levels?", Med Hypotheses, 90, pp.53~56 (2016)
- Peng G, "Timing of newborn blood collection alters metabolic disease screening performance", Front Pediatr, 8, pp.623184~ (2020)
- De Jesús VR, "Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs", Mol Genet Metab, 113, pp.67~75 (2014)
- Flinn AM, "Adenosine deaminase deficiency : a review", Orphanet J Rare Dis, 13, pp.65~ (2018)
- Turgeon CT, "Streamlined determination of lysophosphatidylcholines in dried blood spots for newborn screening of X-linked adrenoleukodystrophy", Mol Genet Metab, 114, pp.46~50 (2015)
- Mashima R, "A selective detection of lysophosphatidylcholine in dried blood spots for diagnosis of adrenoleukodystrophy by LC-MS", MS, 2016, pp.7, 16~19
- Lee S, "Evaluation of X-linked adrenoleukodystrophy newborn screening in North Carolina", JAMA Netw Open, 3, pp.e1920356~ (2020)
- Adam BW, "Performance of succinylacetone assays and their associated proficiency testing outcomes", Clin Biochem, 45, pp.1658~1663 (2012)